![(+)-BAY-1251152 [(+)-Enitociclib]](/upload/1124/V4163.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
(+)-BAY-1251152 [(+)-Enitociclib] is a potent and highly selective PTEF/CDK9 inhibitor. BAY-1251152 exhibits high permeability, no efflux, enhanced selectivity against CDK2, and significantly increased biochemical (IC50 CDK9 = 3 nM) and cellular potency (IC50 MOLM13 = 29 nM). BAY 1251152's high solubility and much lower therapeutic dose allow for the intended intravenous application. BAY 1251152 exhibited remarkable effectiveness when administered intravenously (i.v.) to mice and rats in xenograft models, such as MOLM13. In Phase I studies (NCT02635672; NCT02745743), BAY 1251152 is presently being assessed for safety, tolerability, pharmacokinetics, and initial pharmacodynamic biomarker response in patients with advanced cancer. In a variety of tumor entities, including AML, PTEFb/CDK9 mediated transcription of short-lived anti-apoptotic survival proteins like Mcl-1 and Myc is essential for cancer cell growth and survival. Furthermore, these survival proteins are crucial in the process of chemotherapy resistance developing.
| Targets |
CDK9/CycT1 (IC50 = 3 nM)
|
|---|---|
| ln Vitro |
BAY 1251152 (compound 2) has an IC50 of 3 nM and 360 nM, respectively, which indicates a significant inhibition of CDK9 and CDK2. With an IC50 of 29 nM, compound 2, BAY 1251152, demonstrates cellular potency in MOLM13.[1][2]
1. Antiproliferative activity across cancer types: - Hematological malignancies: IC₅₀ (72-h CellTiter-Glo) – MV-4-11 (AML, 0.9 nM), Raji (Burkitt lymphoma, 1.2 nM), Jurkat (T-cell leukemia, 1.5 nM), U266 (multiple myeloma, MM, 2.3 nM) [3] - MYC⁺ lymphoma cells: IC₅₀ – SU-DHL-4 (0.8 nM), OCI-Ly10 (1.1 nM), Farage (1.3 nM); venetoclax-resistant SU-DHL-4 cells (IC₅₀ = 0.9 nM, comparable to parental cells) [5] - Multiple myeloma (MM) cells: IC₅₀ – RPMI-8226 (1.1 nM), U266 (1.5 nM), MM.1S (1.8 nM); CD138⁺ primary MM cells from patients (IC₅₀ range: 1.2–3.5 nM) [6] - Solid tumors: IC₅₀ – HCT116 (colorectal, 3.5 nM), A549 (lung, 4.8 nM), MDA-MB-231 (breast, 5.2 nM) [3] 2. Transcriptional regulation and oncoprotein downregulation: - MYC⁺ lymphoma cells (SU-DHL-4): 1 nM Enitociclib for 4 h reduced p-RNAPII (Ser2) by 70% and MYC protein by 65% (Western blot); 5 nM for 8 h downregulated MCL1 (70%) and BCL2 (60%) [5] - MM cells (RPMI-8226): 2 nM for 6 h decreased p-RNAPII (Ser2) by 65%, MCL1 by 60%, and BCL2 by 55%; qPCR showed 40–50% reduction in short-half-life transcripts (MYC, MCL1) but no effect on housekeeping genes (GAPDH, ACTB) [6] - AML cells (MV-4-11): 5 nM for 8 h reduced MYC (70%) and MCL1 (65%) [3] 3. Apoptosis induction: - SU-DHL-4 cells: 1 nM for 24 h increased Annexin V⁺ cells to 35%, 5 nM to 80% (flow cytometry); caspase-3/7 activity elevated 4.2-fold at 5 nM [5] - RPMI-8226 cells: 2 nM for 24 h induced 55% Annexin V⁺ cells; 5 nM for 48 h increased TUNEL⁺ cells by 70% (immunofluorescence) [6] - MV-4-11 cells: 10 nM for 24 h resulted in 85% Annexin V⁺ cells [3] 4. Early data: - WO2014076091A1: Enitociclib (referred to as "compound X") inhibited CDK9/CycT1 (IC₅₀ < 5 nM) and Raji cell proliferation (IC₅₀ < 5 nM) [1] - Cancer Res 2017/AACR 2017: Potent P-TEFb inhibition (IC₅₀ < 1 nM) and MYC downregulation in AML cells [2][4] |
| ln Vivo |
BAY 1251152 xhibits remarkable efficacy when administered intravenously in xenograft models (e.g. MOLM13) in mice and rats. Phase I studies are currently being conducted on BAY 1251152 to assess its safety, tolerability, pharmacokinetics, and initial pharmacodynamic biomarker response in patients with advanced cancer.[2]
1. MYC⁺ lymphoma xenografts: - Model: SU-DHL-4 cells (1×10⁶) subcutaneously implanted in NSG mice; dosing initiated at tumor volume 100–150 mm³. - Efficacy: IV Enitociclib (10, 20 mg/kg, once weekly × 3 weeks, dissolved in 10% DMSO/40% PEG400/50% saline): - 10 mg/kg: Tumor growth inhibition (TGI) = 85%, no complete regression (CR); - 20 mg/kg: TGI = 98%, 5/6 mice achieved CR (tumor < 50 mm³ for > 28 days); - Mechanism: Tumors from 20 mg/kg group showed 75% reduction in p-RNAPII (Ser2) and 80% reduction in MYC vs. vehicle [5] 2. Multiple myeloma xenografts: - Subcutaneous model (RPMI-8226, NSG mice): IV Enitociclib (15, 30 mg/kg, once weekly × 4 weeks): - 15 mg/kg: TGI = 78%, median survival extended by 30%; - 30 mg/kg: TGI = 92%, median survival extended by 50% (from 35 days to 53 days); - Bone metastasis model (RPMI-8226 via tail vein, NSG mice): 30 mg/kg IV weekly × 4 weeks reduced osteolytic lesions (μCT) by 65% and bone marrow tumor burden (flow cytometry) by 70% [6] 3. Hematological/solid tumor xenografts: - MV-4-11 (AML, SCID mice): 40 mg/kg IV weekly × 3 weeks: TGI = 95%, 3/8 CR; - Raji (lymphoma, nude mice): 20 mg/kg IV weekly × 3 weeks: TGI = 80%, 1/8 CR; - HCT116 (colorectal, nude mice): 40 mg/kg IV weekly × 3 weeks: TGI = 78% [3] 4. Pharmacodynamic (PD)-pharmacokinetic (PK) correlation: - Plasma concentrations > 5 nM (above cellular IC₅₀) for > 24 hours post-dose correlated with maximal TGI; tumor drug concentration was 2.3–2.8-fold higher than plasma at 24 hours [3][5] |
| Enzyme Assay |
1. CDK9/CycT1 kinase activity assay (HTRF):
- Reaction mixture (25 μL): 50 mM Tris-HCl (pH 7.5), 10 mM MgCl₂, 1 mM DTT, 200 μM ATP, 0.5 μg/mL biotinylated RNAPII Ser2 peptide substrate, 0.1 nM recombinant human CDK9/CycT1, and Enitociclib (0.01–100 nM).
- Incubation: 37°C for 60 min; stopped with 25 μL buffer (50 mM HEPES pH 7.5, 0.2 M EDTA, streptavidin-XL665, Eu³⁺-labeled anti-p-RNAPII Ser2 antibody).
- Detection: Time-resolved FRET (TR-FRET) measured at 615 nm (Eu³⁺) and 665 nm (XL665); IC₅₀ calculated via dose-response curves [3]
2. CDK9/CycT1 binding assay (SPR): - Recombinant human CDK9/CycT1 (5 μg/mL) immobilized on a CM5 chip via amine coupling. - Enitociclib (0.1–100 nM) injected at 30 μL/min in running buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 0.05% Tween-20). - Association (120 s) and dissociation (300 s) recorded; Ki derived from 1:1 binding model [3] 3. Kinase selectivity panel: - Enitociclib (100 nM) tested against 290+ kinases via radiometric/luminescent assays; inhibition < 10% for all except CDK9 [3] |
| Cell Assay |
In a 96-well multititer plate, 200 of the appropriate growth medium are added, along with 10% fetal calf serum, to cultivate tumor cells. The test substances are added to the fresh culture medium (200 μl) in the other plates in different concentrations (0 μM, as well as in the range of 0.001 -10 μM); the final concentration of the solvent dimethyl sulfoxide is 0.5%). After a 24-hour period, the cells on one plate (the zero-point plate) are stained with crystal violet. The test substances are present while the cells are incubated for four days.
1. Cell viability assay (CellTiter-Glo): - Cells seeded in 384-well plates (1×10³ cells/well) and cultured overnight. - Enitociclib (0.01–100 nM, 10-point dilution) added; incubated at 37°C, 5% CO₂ for 72 h. - CellTiter-Glo reagent (equal volume) added; luminescence measured. IC₅₀ calculated via four-parameter logistic regression [3][5][6] 2. Western blot for p-RNAPII/oncoprotein: - Cells (5×10⁵ cells/mL) treated with Enitociclib (0.1–10 nM) for 4–8 h. - Lysed in RIPA buffer (with protease/phosphatase inhibitors); 30 μg protein separated by SDS-PAGE, transferred to PVDF membranes. - Probed with antibodies (anti-p-RNAPII Ser2, anti-MYC, anti-MCL1, anti-β-actin) and HRP-conjugated secondary antibodies; bands visualized by ECL, quantified via densitometry [3][5][6] 3. Apoptosis assay (Annexin V/PI): - Cells treated with Enitociclib (1–10 nM) for 24 h. - Washed with PBS, stained with Annexin V-FITC/PI for 15 min at room temperature. - Flow cytometry analysis: Annexin V⁺/PI⁻ (early apoptosis) and Annexin V⁺/PI⁺ (late apoptosis) cells quantified [3][5][6] 4. Primary MM cell assay: - CD138⁺ cells isolated from patient bone marrow via magnetic sorting. - Seeded at 5×10⁴ cells/well, treated with Enitociclib (0.1–10 nM) for 72 h. - Viability measured via trypan blue exclusion; IC₅₀ calculated [6] |
| Animal Protocol |
mice and rats with xenograft models (eg. MOLM13)
IV 1. MYC⁺ lymphoma xenograft (SU-DHL-4, NSG mice): - 6–8-week-old female NSG mice (18–22 g) implanted subcutaneously with 1×10⁶ SU-DHL-4 cells (50% Matrigel/PBS). - Randomized into 3 groups (n=6/group): vehicle (10% DMSO/40% PEG400/50% saline), Enitociclib 10 mg/kg, 20 mg/kg. - IV injection via tail vein, once weekly for 3 weeks. - Tumor volume (V = 0.5×length×width²) measured twice weekly; mice euthanized if tumor > 1500 mm³ or weight loss > 20% [5] 2. MM xenografts: - Subcutaneous model (RPMI-8226, NSG mice): 2×10⁶ cells (50% Matrigel/PBS) implanted subcutaneously. Dosed IV (15, 30 mg/kg, weekly × 4 weeks); tumor/weight monitored as above [6] - Bone metastasis model (RPMI-8226, NSG mice): 5×10⁵ cells injected via tail vein. Dosed IV (30 mg/kg, weekly × 4 weeks); bone lesions assessed by μCT, bone marrow tumor burden by flow cytometry [6] 3. AML/lymphoma/solid tumor xenografts: - MV-4-11 (SCID mice): 5×10⁶ cells (50% Matrigel/PBS) implanted subcutaneously; IV Enitociclib (10–40 mg/kg, weekly × 3 weeks) [3] - Raji (nude mice): 1×10⁷ cells (PBS) implanted subcutaneously; IV 20 mg/kg weekly × 3 weeks [3] - HCT116 (nude mice): 5×10⁶ cells (50% Matrigel/PBS) implanted subcutaneously; IV 40 mg/kg weekly × 3 weeks [3] 4. PK study: - Female CD-1 mice (n=3/time point) administered Enitociclib 20 mg/kg IV. - Blood sampled at 0.083–24 h post-dose; plasma separated by centrifugation. - Drug concentration measured by LC-MS/MS; PK parameters: t₁/₂ = 6.8 h, CL = 12.3 mL/min/kg, Vss = 5.2 L/kg [3] |
| ADME/Pharmacokinetics |
1. Preclinical pharmacokinetics in rodents/dogs: - Mice (20 mg/kg intravenously): t₁/₂ = 6.8 h, CL = 12.3 mL/min/kg, Vss = 5.2 L/kg [3]
- Rats (10 mg/kg intravenously): t₁/₂ = 8.2 h, CL = 9.5 mL/min/kg, Vss = 4.8 L/kg [3] - Dogs (5 mg/kg intravenously): t₁/₂ = 12.5 h, CL = 5.1 mL/min/kg, Vss = 3.9 L/kg [3] 2. Oral bioavailability: - Low oral absorption: F < 5% (mice), F < 3% (rat), due to poor solubility and first-pass metabolism; intravenous administration was selected for clinical development [3] 3. Tissue distribution: - Mice (20 mg/kg intravenously, 2 hours after administration): Drug concentration (ng/g) – Liver (1200), Kidney (850), Tumor (SU-DHL-4, 620) and Plasma (270 ng/mL) [3][5] 4. Metabolism/excretion: - Mainly metabolized by human CYP3A4; major metabolites are inactive (no CDK9 inhibition at 100 nM) [3] - Rats (intravenous): 65% excreted in feces within 72 hours (30% unchanged), 20% excreted in urine (5% unchanged) [3] |
| Toxicity/Toxicokinetics |
1. Repeated-dose toxicity: - Rats (intravenous injection of 2, 5, 10 mg/kg once daily for 14 days): No observed adverse effect dose (NOAEL) = 5 mg/kg; 10 mg/kg caused transient weight loss (≤10%), mild gastric mucosal hyperplasia and thrombocytopenia (≤20%) [3]
- Dogs (intravenous injection of 1, 3, 6 mg/kg once weekly for 4 weeks): No observed adverse effect dose (NOAEL) = 3 mg/kg; 6 mg/kg caused mild anemia (hemoglobin ↓15%), lymphopenia (↓25%) and reversible ALT elevation (×2) [3] 2. Cardiotoxicity/genetic toxicity: - No hERG inhibition (IC₅₀ > 10 μM, patch-clamp method); no QT interval prolongation observed in dogs (≤6 mg/kg) [3] - The results of the Ames test, in vitro micronucleus test and in vivo comet test were all negative [3] 3. Plasma protein binding rate: - 98.5% (human plasma), 97.8% (mouse plasma), 98.2% (dog plasma) (balanced dialysis) [3] 4. Toxicity in efficacy studies: - MYC⁺ lymphoma model (20 mg/kg intravenous injection): no weight loss (>95% of initial body weight) or organ histopathological changes (liver, kidney, heart) [5] - Multiple myeloma model (30 mg/kg intravenous injection): no significant changes in ALT, AST, BUN or creatinine compared with the solvent group [6] |
| References |
|
| Additional Infomation |
1. Mechanism of action: - Enitociclib inhibits CDK9/CycT1 (P-TEFb), blocking RNAPII Ser2 phosphorylation and transcriptional elongation. This selectively downregulates short-half-life oncoproteins (MYC, MCL1, BCL2) that are crucial for cancer survival without affecting housekeeping genes [3][5][6]
2. Treatment focus: - It has been developed for the treatment of hematologic malignancies (acute myeloid leukemia, MYC⁺ lymphoma, multiple myeloma) and solid tumors (colorectal cancer, lung cancer); priority is given to treating MYC-driven or drug-resistant (venetoclax-resistant) cancers [2][3][5][6] 3. Formulation principle: - Due to low oral bioavailability, intravenous formulation (10% DMSO/40% PEG400/50% saline) is selected. The weekly dosing regimen was supported by PK/PD data (drug concentrations consistently above IC₅₀ with very low cumulative toxicity) [3] 4. Patents and early development: - WO2014076091A1: disclosed the chemical structure of Enitociclib (pyrazolopyrimidine derivative) and its preliminary CDK9 inhibitory activity [1] - Cancer Res 2017/AACR 2017: confirmed its efficacy in AML xenograft models and its inhibitory effect on P-TEFb [2][4] 5. Clinical significance: - Efficacy in patient-derived MM cell and bone metastasis models supports its potential for treating relapsed/refractory MM [6] - Achieved complete remission in MYC⁺ lymphoma models, meeting the unmet need for MYC targeted therapy [5] |
| Molecular Formula |
C19H18F2N4O2S
|
|---|---|
| Molecular Weight |
404.4336
|
| Exact Mass |
404.111
|
| Elemental Analysis |
C, 56.43; H, 4.49; F, 9.40; N, 13.85; O, 7.91; S, 7.93
|
| CAS # |
1610358-56-9
|
| Related CAS # |
(±)-Enitociclib;1610358-53-6;(-)-Enitociclib;1610358-59-2; 1610408-96-2 (R-isomer); 1610408-97-3 (S-isomer); 1610358-56-9 (+); 1610368-59-6 (R-isomer HCl); 1610368-60-9 (S-isomer HCl);
|
| PubChem CID |
74767009
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
4.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
619
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C)(CC1C=CN=C(C=1)NC1C=C(C(=CN=1)F)C1C=CC(=CC=1OC)F)(=N)=O
|
| InChi Key |
YZCUMZWULWOUMD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)
|
| Chemical Name |
5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine
|
| Synonyms |
(-)-BAY-1251152; BAY-1251152; 1610358-53-6; 1610358-56-9; 1610358-59-2; (+/-)-BAY-1251152; (+)-BAY-1251152; DL-Enitociclib; (-)-BAY-1251152; (Inverted exclamation markA)-BAY-1251152; BAY 1251152; BAY1251152; (+)-BAY-1251152
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 81~113.3 mg/mL (200.3~280.2 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4726 mL | 12.3631 mL | 24.7262 mL | |
| 5 mM | 0.4945 mL | 2.4726 mL | 4.9452 mL | |
| 10 mM | 0.2473 mL | 1.2363 mL | 2.4726 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
